CA2927557C - Use of ll-37 to treat chronic ulcers - Google Patents

Use of ll-37 to treat chronic ulcers Download PDF

Info

Publication number
CA2927557C
CA2927557C CA2927557A CA2927557A CA2927557C CA 2927557 C CA2927557 C CA 2927557C CA 2927557 A CA2927557 A CA 2927557A CA 2927557 A CA2927557 A CA 2927557A CA 2927557 C CA2927557 C CA 2927557C
Authority
CA
Canada
Prior art keywords
ulcer
pharmaceutical formulation
wound
formulation
per
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2927557A
Other languages
English (en)
French (fr)
Other versions
CA2927557A1 (en
Inventor
Alvar Gronberg
Christine DIETERICH
Margit Mahlapuu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pergasus AB
Original Assignee
Pergasus AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pergasus AB filed Critical Pergasus AB
Publication of CA2927557A1 publication Critical patent/CA2927557A1/en
Application granted granted Critical
Publication of CA2927557C publication Critical patent/CA2927557C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0019—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0085—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Materials Engineering (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2927557A 2013-11-19 2014-11-19 Use of ll-37 to treat chronic ulcers Active CA2927557C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/GB2013/053053 WO2015075406A1 (en) 2013-11-19 2013-11-19 New treatment of chronic ulcers
GBPCT/GB2013/053053 2013-11-19
PCT/GB2014/053415 WO2015075441A1 (en) 2013-11-19 2014-11-19 New treatment of chronic ulcers

Publications (2)

Publication Number Publication Date
CA2927557A1 CA2927557A1 (en) 2015-05-28
CA2927557C true CA2927557C (en) 2023-05-02

Family

ID=49998562

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2927557A Active CA2927557C (en) 2013-11-19 2014-11-19 Use of ll-37 to treat chronic ulcers

Country Status (15)

Country Link
US (3) US10226508B2 (https=)
EP (1) EP3071216B1 (https=)
JP (1) JP6539268B2 (https=)
KR (1) KR102360938B1 (https=)
CN (1) CN105939726A (https=)
AU (1) AU2014351607B2 (https=)
BR (1) BR112016011166A8 (https=)
CA (1) CA2927557C (https=)
ES (1) ES2925876T3 (https=)
MX (1) MX379357B (https=)
PL (1) PL3071216T3 (https=)
RU (1) RU2707254C1 (https=)
TW (1) TWI698251B (https=)
WO (2) WO2015075406A1 (https=)
ZA (1) ZA201604110B (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0808376D0 (en) 2008-05-08 2008-06-18 Bristol Myers Squibb Co Wound dressing
GB0817796D0 (en) 2008-09-29 2008-11-05 Convatec Inc wound dressing
GB201020236D0 (en) 2010-11-30 2011-01-12 Convatec Technologies Inc A composition for detecting biofilms on viable tissues
PL2648795T3 (pl) 2010-12-08 2023-05-08 Convatec Technologies Inc. System do usuwania wysięków z miejsca rany
JP5965409B2 (ja) 2010-12-08 2016-08-03 コンバテック・テクノロジーズ・インコーポレイテッドＣｏｎｖａｔｅｃ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ 創傷滲出液を評価するための統合システム
CN103347562B (zh) 2010-12-08 2016-08-10 康沃特克科技公司 伤口分泌液系统附件
GB201115182D0 (en) 2011-09-02 2011-10-19 Trio Healthcare Ltd Skin contact material
GB2497406A (en) 2011-11-29 2013-06-12 Webtec Converting Llc Dressing with a perforated binder layer
GB201120693D0 (en) 2011-12-01 2012-01-11 Convatec Technologies Inc Wound dressing for use in vacuum therapy
JP2016507663A (ja) 2012-12-20 2016-03-10 コンバテック・テクノロジーズ・インコーポレイテッドＣｏｎｖａｔｅｃ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ 化学修飾セルロース系繊維の加工
WO2015075406A1 (en) 2013-11-19 2015-05-28 Lipopeptide Ab New treatment of chronic ulcers
JP6738833B2 (ja) 2015-04-28 2020-08-12 コンバテック・テクノロジーズ・インコーポレイテッドＣｏｎｖａｔｅｃ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ 抗細菌性ナノファイバー
GB2543544A (en) 2015-10-21 2017-04-26 Brightwake Ltd Wound dressing
WO2017173069A1 (en) 2016-03-30 2017-10-05 Convatec Technologies Inc. Detecting microbial infections in wounds
WO2017212345A2 (en) 2016-03-30 2017-12-14 Synovo Gmbh Detecting microbial infection in wounds
GB201608099D0 (en) 2016-05-09 2016-06-22 Convatec Technologies Inc Negative pressure wound dressing
JP7071957B2 (ja) 2016-07-08 2022-05-19 コンバテック・テクノロジーズ・インコーポレイテッド 可撓性陰圧システム
BR112019000284A2 (pt) 2016-07-08 2019-04-16 Convatec Technologies Inc. aparelho de coleta de fluido
ES2912094T3 (es) 2016-07-08 2022-05-24 Convatec Technologies Inc Detección de flujo de fluidos
US11795192B2 (en) 2017-03-10 2023-10-24 Lakewood Amedex, Inc. Antimicrobial compounds, compositions, and uses thereof
FI3638251T3 (fi) 2017-06-12 2024-04-29 Lakewood Amedex Inc Bisfosfosiinin geeliformulaatioita ja niiden käyttötapoja
US12161792B2 (en) 2017-11-16 2024-12-10 Convatec Limited Fluid collection apparatus
SG11202103180QA (en) 2018-10-17 2021-05-28 Lakewood Amedex Inc Methods and compositions for treating oral mucositis
EP4295869B1 (en) 2019-06-03 2026-01-28 Convatec Limited Devices to disrupt and contain pathogens
US11771819B2 (en) 2019-12-27 2023-10-03 Convatec Limited Low profile filter devices suitable for use in negative pressure wound therapy systems
US11331221B2 (en) 2019-12-27 2022-05-17 Convatec Limited Negative pressure wound dressing

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5271943A (en) * 1989-10-27 1993-12-21 Scott Health Care Wound gel compositions containing sodium chloride and method of using them
US5641483A (en) * 1995-06-07 1997-06-24 Beaulieu; Andre Wound healing formulations containing human plasma fibronectin
EP0935965A4 (en) 1996-04-23 2002-01-23 Toray Industries SUBSTANCE AGAINST PYLORI
EP0928206B1 (en) * 1996-07-11 2004-04-14 Coloplast A/S A hydrocolloid wound gel
US6861067B2 (en) * 1998-09-17 2005-03-01 Sherwood Services Ag Hydrogel wound dressing and the method of making and using the same
US6835713B2 (en) 2001-02-16 2004-12-28 University Of Pittsburgh Virus derived antimicrobial peptides
EP1358888A1 (en) 2002-02-28 2003-11-05 Robert Bals The human peptide antibiotic LL-37/hCAP-18 is an inducer of angiogenesis
SE0300207D0 (sv) 2003-01-29 2003-01-29 Karolinska Innovations Ab New use and composition
US7262179B2 (en) * 2003-05-28 2007-08-28 Bristol-Myers Squibb Company Wound care compositions
EP1621205A1 (en) * 2004-07-28 2006-02-01 OctoPlus Technologies B.V. Antimicrobial peptides derived from CAP18
ZA200600686B (en) * 2006-01-24 2006-04-26 Jacobus F Mouton A wound dressing
WO2008088922A2 (en) * 2007-01-19 2008-07-24 Genentech, Inc. Prevention of hydrogel viscosity loss
CN101720237A (zh) * 2007-06-25 2010-06-02 利波佩普蒂德有限公司 新型医用产品
CA2734577A1 (en) * 2007-08-16 2009-02-26 Carnegie Mellon University Inflammation-regulating compositions and methods
US9101586B2 (en) 2007-12-28 2015-08-11 Augustine Bader Topical application and formulation of erythropoietin for skin wound healing
AU2010316006B2 (en) 2009-11-03 2013-09-26 Lipidor Ab Composition for promoting wound healing
CA2810844C (en) * 2010-09-07 2017-03-21 Dmi Acquisition Corp. Diketopiperazine compositions for the treatment of metabolic syndrome and related conditions
US9693936B2 (en) * 2012-03-07 2017-07-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Dispersions in oil of Dead Sea nano sized material preparation and uses therof
WO2013163423A1 (en) * 2012-04-25 2013-10-31 Musc Foundation For Research Development Compositions and methods for wound healing and tissue repair
WO2015075406A1 (en) 2013-11-19 2015-05-28 Lipopeptide Ab New treatment of chronic ulcers

Also Published As

Publication number Publication date
EP3071216B1 (en) 2022-08-03
JP2016537373A (ja) 2016-12-01
EP3071216A1 (en) 2016-09-28
BR112016011166A2 (https=) 2017-08-08
MX2016006091A (es) 2016-12-09
MX379357B (es) 2025-03-11
AU2014351607B2 (en) 2020-03-05
RU2016124234A (ru) 2017-12-25
KR20160088914A (ko) 2016-07-26
ZA201604110B (en) 2020-11-25
US20200384077A1 (en) 2020-12-10
AU2014351607A1 (en) 2016-06-23
TWI698251B (zh) 2020-07-11
KR102360938B1 (ko) 2022-02-09
TW201521760A (zh) 2015-06-16
CA2927557A1 (en) 2015-05-28
US10226508B2 (en) 2019-03-12
US10709760B2 (en) 2020-07-14
US20190255147A1 (en) 2019-08-22
PL3071216T3 (pl) 2022-11-21
BR112016011166A8 (pt) 2022-06-28
WO2015075406A1 (en) 2015-05-28
ES2925876T3 (es) 2022-10-20
RU2707254C1 (ru) 2019-11-25
CN105939726A (zh) 2016-09-14
JP6539268B2 (ja) 2019-07-03
US20160271217A1 (en) 2016-09-22
US11191810B2 (en) 2021-12-07
WO2015075441A1 (en) 2015-05-28

Similar Documents

Publication Publication Date Title
US11191810B2 (en) Treatment of chronic ulcers
Belmin et al. Sequential treatment with calcium alginate dressings and hydrocolloid dressings accelerates pressure ulcer healing in older subjects: a multicenter randomized trial of sequential versus nonsequential treatment with hydrocolloid dressings alone
Alvarez et al. Incorporating wound healing strategies to improve palliation (symptom management) in patients with chronic wounds
KR20120022930A (ko) 은 설파디아진 및 키토산을 사용하여 제조한 약용 크림 및 이의 제조 방법
RU2014137827A (ru) Композиции и применение противомикробных материалов со свойствами биологической совместимости
Abboud et al. Do silver-based wound dressings reduce pain? A prospective study and review of the literature
JP6169693B2 (ja) 次亜塩素酸およびアミノ酸を含む創傷およびびらんを治療するための製剤
Whitmont et al. Treatment of chronic diabetic lower leg ulcers with activated protein C: a randomised placebo‐controlled, double‐blind pilot clinical trial
Scalise et al. Enzymatic debridement: is HA-collagenase the right synergy? Randomized double-blind controlled clinical trial in venous leg ulcers.
Karri et al. Understanding the implications of pharmaceutical excipients and additives in the treatment of diabetic foot ulcers
Brown et al. Randomized standard-of-care-controlled trial of a silica gel fibre matrix in the treatment of chronic venous leg ulcers
US11938173B2 (en) Use of Clostridium histolyticum protease mixture in promoting wound healing
HK1229249A1 (en) New treatment of chronic ulcers
HK1229249B (en) New treatment of chronic ulcers
Ryan Current management of leg ulcers
Elgayyar et al. Evaluation of chitosan impregnated with silver nanoparticles in the treatment of chronic venous leg ulcer: an open-label controlled study
Kasisomayajula Efficacy of collagen sheet dressings for donor site in split skin grafting
Bianchi Iodoflex and Iodosorb in the treatment of venous leg ulcers
IL303383A (en) Compositions and methods for treating wounds
Reddy Karri et al. Understanding the implications of pharmaceutical excipients and additives in the treatment of diabetic foot ulcers.
Humbert et al. Allaert

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190927

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251001

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260108

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260112

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260112